High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of Chromatography B: Biomedical Sciences and Applications

• Publication date

  1999-03-19

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0378-4347(98)00565-9PMID 10219677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Organ-specific biotransformation of ormaplatin in the Fischer 344 rat

  2004cited by this paper
• Comparisons of tetrachloro(d,l-trans)1,2-diaminocyclohexaneplatinum(IV) biotransformations in the plasma of Fischer 344 rats at therapeutic and toxic doses

  2004cited by this paper
• Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial

  2004cited by this paper
• Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits

  2004cited by this paper
• Cytotoxicity, accumulation, and efflux of cisplatin and its metabolites in human ovarian carcinoma cells.

  1996cited by this paper
• Comparative pharmacokinetics of oxaliplatin (L‐OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing time

  1994cited by this paper
• New Cisplatin Analogues in Development

  1993cited by this paper
• A chronopharmacologic phase II clinical trial with 5‐fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer

  1992cited by this paper
• Ovarian cancer: new clinical approaches.

  1991cited by this paper
• An unexpected biotransformation pathway for tetrachloro-(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in the L1210 cell line.

  1991cited by this paper
• In vitro biotransformations of tetrachloro(d,l-trans)-1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in rat plasma.

  1990cited by this paper
• Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum.

  1989cited by this paper
• Rapid reduction of tetrachloro(D,L-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) in RPMI 1640 tissue culture medium.

  1989cited by this paper
• Tritiated platinum antitumor agents containing the trans‐(d,1)‐1,2‐diaminocyclohexane carrier ligand

  1988cited by this paper
• Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line.

  1988cited by this paper
• High-performance liquid chromatographic separation of platinum complexes containing the cis-1,2-diaminocyclohexane carrier ligand.

  1986cited by this paper
• Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.

  1984cited by this paper
• Monitoring the reactions of cisplatin with nucleotides and methionine by reversed-phase high-performance liquid chromatography using cationic and anionic pairing ions.

  1983cited by this paper
• Cancer Chemotherapy Annual 2

  1983cited by this paper
• High-performance liquid chromatography of cis-dichlorodiammineplatinum(II) using chemically-bonded and solvent-generated ion exchangers

  1981cited by this paper
• Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers.

  1980cited by this paper
• Biological handbooks. Blood and other body fluids.

  1961cited by this paper

• Designing a Mucoadhesive ChemoPatch to Ablate Oral Dysplasia for Cancer Prevention.

  2022cites this paper
• Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats

  2021cites this paper
• Development, optimization and in vitro evaluation of oxaliplatin loaded nanoparticles in non-small cell lung cancer

  2020cites this paper
• Irinotecan or Oxaliplatin: Which is the First Move for the Mate?

  2020cites this paper
• Synthesis, Characterization, Cytotoxicity, and Time-Dependent NMR Spectroscopic Studies of (SP -4-3)-Oxalato[(1R ,2R ,4R /1S ,2S ,4S )-(4-trifluoromethyl-cyclohexane-1,2-diamine)]platinum(II)

  2019cites this paper
• A validated inductively coupled plasma mass spectrometry (ICP‐MS) method for the quantification of total platinum content in plasma, plasma ultrafiltrate, urine and peritoneal fluid

  2018cites this paper
• Transport of oxaliplatin species in water-saturated natural soil.

  2018cites this paper
• Synthesis, Characterization, and Time‐Dependent NMR Spectroscopy Studies of (SP‐4‐2)‐[(trans‐1R,2R/1S,2S‐15N2)‐Cyclohexane‐1,2‐diamine][(13C2)oxalato]platinum(II)

  2017cites this paper
• Anwendung der Platinspeziation zum Nachweis einer Aktivierung oder Inhibierung von Pt enthaltenden Krebsmedikamenten

  2014cites this paper
• Synthesis, Characterization and in Vitro Antitumor Activity of Platinum(II) Oxalato Complexes Involving 7-Azaindole Derivatives as Coligands

  2014cites this paper
• Luteolin potentiates the sensitivity of colorectal cancer cell lines to oxaliplatin through the PPAR&ggr;/OCTN2 pathway

  2014cites this paper
• Investigating the genetics and pharmacogenetics of bowel cancer

  2013cites this paper
• Antitumor effect of miriplatin-lipiodol suspension/emulsion using a VX2 liver tumor model

  2013cites this paper
• Defining the role of MRP-mediated efflux and glutathione in detoxification of oxaliplatin.

  2013cites this paper
• Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells

  2012cites this paper
• A full validated hydrophilic interaction liquid chromatography-tandem mass spectrometric method for the quantification of oxaliplatin in human plasma ultrafiltrates.

  2012cites this paper
• Comparison of the Anti-tumor Effects of Two Platinum Agents (Miriplatin and Fine-Powder Cisplatin)

  2012influential citation
• Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance

  2011cites this paper
• Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting

  2011cites this paper
• Synthesis, characterization, structure, molecular modeling studies and biological activity of sterically crowded Pt(II) complexes containing bis(imidazole) ligands.

  2011cites this paper
• Ultra-fast HPLC-ICP-MS analysis of oxaliplatin in patient urine

  2010cites this paper
• Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives

  2010cites this paper
• Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs.

  2010cites this paper
• Matrix-assisted laser desorption/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney.

  2010cites this paper
• Mami Murakami Subcellular Targeting Improving Drug Potency and Efficacy by Nanocarrier-Mediated

  2010cites this paper
• MECHANISMS OF EFFECTS OF PLATINUM ( II ) AND ( IV ) COMPLExES . COMPARISON OF CISPLATIN AND OxALIPLATIN wITH SATRAPLATIN AND LA-12 , NEw PT ( IV )-BASED DRUGS

  2009cites this paper
• New insights into the biotransformation and pharmacokinetics of oxaliplatin.

  2009cites this paper
• Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency.

  2009cites this paper
• Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis

  2008cites this paper
• A study of oxaliplatin–nucleobase interactions using ion trap electrospray mass spectrometry

  2008cites this paper
• MECHANISMS OF EFFECTS OF PLATINUM (II) AND (IV) COMPLExES. COMPARISON OF CISPLATIN AND OxALIPLATIN wITH SATRAPLATIN AND LA-12, NEw PT(IV)-BASED DRUGS. A MINIREVIEw

  2008cites this paper
• BIOTRANSFORMATION OF THE ANTINEOPLASTIC DRUG OXALIPLATIN: IMPORTANCE FOR EFFECTS AND SIDE EFFECTS

  2008influential citation
• The activation of platinum(II) antiproliferative drugs in carbonate medium evaluated by means of a DNA-biosensor.

  2007cites this paper
• Direct cellular responses to platinum-induced DNA damage.

  2007cites this paper
• Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improved tumor targeting and enhanced antitumor activity.

  2007cites this paper
• Role of carbonate in the cytotoxicity of carboplatin.

  2007cites this paper
• Fate of cancerostatic platinum compounds in biological wastewater treatment of hospital effluents.

  2007cites this paper
• The relation between stereochemistry and biological activity of platinum(II) complexes chelated with chiral diamine ligands: an intricate problem.

  2007cites this paper
• Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

  2006cites this paper
• Novel separation method for highly sensitive speciation of cancerostatic platinum compounds by HPLC–ICP–MS

  2005cites this paper
• Palladium(II) diamine complex induces reduction of glutathione disulfide.

  2004cites this paper
• Tumour-inhibiting platinum complexes--state of the art and future perspectives.

  2003cites this paper
• Sensitive species-specific monitoring of a new triplatinum anti-cancer drug and its potential related compounds in spiked human plasma by cation-exchange HPLC-ICP-MS

  2003cites this paper
• Capillary electrophoresis in anti‐cancer metallodrug research: Advances and future challenges

  2003cites this paper
• Cellular and molecular pharmacology of oxaliplatin.

  2002cites this paper
• Oxaliplatin biotransformation and pharmacokinetics: a pilot study to determine the possible relationship to neurotoxicity.

  2002cites this paper
• Oxaliplatin: A Review of Evolving Concepts

  2002cites this paper
• Cellular and Molecular Pharmacology of Oxaliplatin 1

  2002cites this paper
• Drugs of the Future: Review Cellular and molecular aspects of drugs of the future: oxaliplatin

  2002cites this paper
• Cellular and molecular aspects of drugs of the future: oxaliplatin

  2002cites this paper
• [Preclinical studies of oxaliplatin in combination chemotherapy].

  2001cites this paper
• Speciation of platinum compounds: a review of recent applications in studies of platinum anticancer drugs.

  2001cites this paper
• Oxaliplatin and Chronopharmacological Aspects

  2000cites this paper
• Liquid chromatography-mass spectrometry in the study of the metabolism of drugs and other xenobiotics.

  2000cites this paper
• Oxaliplatin: pharmacokinetics and chronopharmacological aspects.

  2000cites this paper
• Oxaliplatin-induced damage of cellular DNA.

  2000cites this paper